A critical evaluation of the cost-effectiveness of radon protection methods in new homes in a radon Affected Area of England

Environment International

Volumn 35, Issue 6, 2009, Pages 943-951

  Coskeran, Thomas ^a   Denman, Antony ^b   Phillips, Paul ^b   Tornberg, Roger ^c  

^a DURHAM UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NORTHAMPTON   (United Kingdom)

^c Radon Centres Ltd   (United Kingdom)

Author keywords

Bootstrapping; Building regulations; Cost effectiveness analysis; Lung cancer; Radon remediation

Indexed keywords

BIOLOGICAL ORGANS; BUILDING CODES; CONSTRUCTION INDUSTRY; COST EFFECTIVENESS; COST ESTIMATING; COSTS; DISEASES; RADON; STATISTICAL METHODS;

BOOTSTRAP TECHNIQUE; BOOTSTRAPPING; BUILDING REGULATIONS; COST EFFECTIVENESS ANALYSIS; CRITICAL EVALUATION; GOVERNMENT DEPARTMENTS; LUNG CANCER; QUALITY ADJUSTED LIFE YEARS;

COST BENEFIT ANALYSIS;

RADON;

BOOTSTRAPPING; BUILDING CODE; CONFIDENCE INTERVAL; INSTALLATION; POLLUTION EXPOSURE; PUBLIC HEALTH; RADON; REGULATORY APPROACH;

ARTICLE; BOOTSTRAPPING; BUILDING INDUSTRY; COST EFFECTIVENESS ANALYSIS; GOVERNMENT REGULATION; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY OF LIFE; RADIATION EXPOSURE; RADIATION PROTECTION; RESIDENTIAL HOME; UNITED KINGDOM;

BRIXWORTH; ENGLAND; EURASIA; EUROPE; NORTHAMPTONSHIRE; UNITED KINGDOM; WESTERN EUROPE;

EID: 67349157693     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2009.04.004     Document Type: Article

References (54)

1. Allsup S., Haycox A., Regan M., and Gosney M. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years?: A randomised controlled trial. Vaccine 23 5 (2004) 639-645
2. Arthur A.T. Lung cancer risk from exposure to radon in the home: are policies in the United Kingdom appropriate to the risk?. Healthy housing: promoting good health (2003), University of Warwick, Coventry
3. Barr R., Feeny D., and Furlong W. Economic evaluation of treatments for cancer in childhood. Eur J Cancer 40 9 (2004) 1335-1345
4. Bradley E.J. Responses to radon remediation advice. Proc. 9th Int. Congress International Radiation Protection Association. 4-798-4-800 (1996)
5. Bradley E.J., Lomas P.R., Green B.M.R., and Smithard J. Radon in dwellings in England: 1997 review. National Radiological Protection Board report (NRPB) R293 (1997), NRPB, Chilton, Oxon, UK
6. BRE (Building Research Establishment). Radon: guidance on protective measures for new dwellings 1992 edition. BRE report BR211 (1992), BRE, Garston, Herts, UK
7. BRE (Building Research Establishment). Radon: guidance on protective measures for new dwellings 1999 edition. BRE report BR211 (1999), BRE, Garston, Herts, UK
8. Campbell M.K., and Torgerson D.J. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. QJM 92 3 (1999) 177-182
9. Chow Y., Green B.M.R., Zhang W., and Meara J. Radon health equity audit - is the radon programme fair?. Health protection 2007 (2007), University of Warwick
10. Clegg A., Scott D.A., Sidhu M., Hewitson P., and Waugh N. Clinical and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer: a systematic review. Thorax 57 1 (2002) 20-28
11. Coskeran T., Denman A.R., Phillips P.S., and Tornberg R. A cost-effectiveness analysis of domestic radon remediation in four primary care trusts located in Northamptonshire, UK. Health Policy 71 1 (2005) 43-56
12. Coskeran T., Denman A.R., Phillips P.S., and Tornberg R. A cost-effectiveness analysis of radon protection methods in domestic properties: a comparative case study in Brixworth, Northamptonshire, UK. J Environ Radioact 91 1-2 (2006) 73-89
13. Coskeran T., Denman A.R., Phillips P.S., and Tornberg R. The cost-effectiveness of radon-proof membranes in new homes: a case study from Brixworth, Northamptonshire, UK. Health Policy 81 2-3 (2007) 195-206
14. Darby S., Hill R., and Doll R. Radon: a likely carcinogen at all exposures. Ann Oncol 12 10 (2001) 1341-1351
15. Darby S., Hill D., Auvinen A., Barros-Dios J.M., Baysson H., Bochicchio F., et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. Br Med J 330 (2005) 223-228
16. Darby S., Hill D., Auvinen A., Barros-Dios J.M., Baysson H., Bochicchio F., et al. Residential radon and lung cancer-detailed results of a collaborative analysis of individual data on 7148 persons with lung cancer and 14,208 persons without lung cancer from 13 epidemiologic studies in Europe. Scand J Work Environ Health 32 Suppt. 1 (2006) 1-84
17. Denman A.R., and Phillips P.S. A review of the cost effectiveness of radon mitigation in domestic properties in Northamptonshire. J Radiol Prot 18 (1998) 119-124
18. Denman A.R., Phillips P.S., and Tornberg R. A comparison of the costs and benefits of radon remediation programmes in new and existing houses in Northamptonshire. J Environ Manag 59 1 (2000) 21-30
19. Denman A.R., Eatough J.P., Gillmore G., and Phillips P.S. Assessment of health risks to skin and lung from elevated levels in abandoned mines. Health Phys 85 6 (2003) 733-739
20. Denman A.R., Phillips P.S., Groves-Kirkby C.J., and Crockett R.M. Do radon-proof membranes reduce radon levels adequately in new houses?. Proceedings of the seventh SRP international symposium; Cardiff, 12-17 June (2005)
21. Department of Health. Health survey for England 1996 (1998), Stationery Office, London
22. Department of Health. NHS cancer plan (2000), Department of Health, London
23. Department of Health. Cancer reform strategy (2007), Central Office for Information, London
24. Dinnes J., Cave C., Huang S., Major K., and Milne R. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review. Health Technol Assess 5 13 (2001)
25. Efron B., and Tibshirani R. An introduction to the bootstrap (1993), Chapman and Hall, London
26. Environmental Radon Newsletter. Health Protection Agency Board gives advice on radon measures for new homes. Autumn 2008 vol. 56 (1) (2008), NRPB, Chilton, Oxon, UK
27. Fiscella K., and Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. J Am Med Assoc 275 16 (1996) 1247-1251
28. Green B.M.R., Miles J.C.H., Bradley E.J., and Rees D.M. Radon atlas of England and Wales. National Radiological Protection Board (NRPB) report W26 (2002), NRPB, Chilton, Oxon, UK
29. Groves-Kirkby C.J., Denman A.R., Phillips P.S., Crockett R.G.M., Woolridge A.C., and Tornberg R. Radon mitigation in domestic properties and its health implications - a comparison between during-construction and post-construction radon reduction. Environ Int 32 4 (2006) 435-443
30. Groves-Kirkby C.J., Denman A.R., Crockett R.G.M., Phillips P.S., Woolridge A.C., and Gillmore G.K. Time-integrating radon gas measurements in domestic properties: comparison of short, medium and long term exposures. J Environ Radioact 86 1 (2006) 92-109
31. Groves-Kirkby C.J., Denman A.R., Phillips P.S., Tornberg R., Woolridge A.C., and Crockett R.G.M. Domestic radon remediation of U.K. dwellings by sub-slab depressurisation: evidence for a baseline contribution from constructional materials. Environ Int 34 3 (2008) 428-436
32. Her Majesty 's Treasury. The green book: appraisal and evaluation in central government (2003), The Stationery Office, London
33. Hughes J.S. Ionising radiation exposure of the UK population: 1999 review. National Radiological Protection Board (NRPB) report R311 (1999), NRPB, Chilton, Oxon, UK
34. Kreienbrock L., Kreuzer M., Gerken M., Dingerkus G., Wellmann J., Keller G., and Wichmann H.E. Case-control study on lung-cancer and residential radon in Western Germany. Am J Epidemiol 153 (2001) 42-52
35. Krewski D., Lubin J.H., Zielinski J.M., Alavanja M., Catalan V.S., William F.R., et al. Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology 16 (2005) 137-145
36. Krewski D., Lubin J.H., Zielinski J.M., Alavanja M., Catalan V.S., William F.R., et al. A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health 69 7-8 (2006) 533-597
37. Lubin J., and Boice J.D. Lung cancer risk from residential radon: a meta-analysis of eight epidemiological studies. J Natl Cancer Inst 89 1 (1997) 49-57
38. Marshall D., Simpson K.N., Earle C.C., and Chu C.-W. Economic decision analysis model of screening for lung cancer. Eur J Cancer 37 (2001) 1759-1767
39. Mason J., Drummond M., and Torrance G. Some guidelines on the use of cost-effectiveness league tables. Br Med J 306 6877 (1993) 570-572
40. Miles J.C.H. Mapping radon-prone areas by lognormal modelling of house radon data. Health Phys 74 3 (1998) 270-278
41. Miles J.C.H., and Appleton J.D. Mapping variations in radon potential both between and within geological units. J Radiol Prot 25 3 (2005) 257-276
42. National Radiological Protection Board (NRPB). Statement on human exposure to radon in homes. Doc NRPB 1 1 (1990) 17-32
43. National Radiological Protection Board (NRPB). Radon affected areas, Derbyshire, Northamptonshire and Somerset. Doc NRPB 3 (1992) 18-28
44. Office for the Deputy Prime Minister. Sustainable communities: building for the future (the sustainable communities plan) (2003), The Stationery Office, London
45. Phillips P., Fraser J., and Denman A.R. Effectiveness of secondary radon protection in Northamptonshire homes. Environ Manag Health 11 (2000) 337-351
46. Radon Council Ltd The. The radon manual: a guide to the requirements for the detection and measurement of natural radon levels associated with remedial measures and subsequent monitoring of results (1995), Radon Council, London
47. Scivyer C.R. Radon protection for new buildings: a practical solution from the UK. Sci Total Environ 272 (2001) 91-96
48. Scivyer C.R., and Noonan K. Long-term reduction of very high radon levels. Environmental Radon Newsletter Chilton vol. 26 (2001), NRPB, Oxon, UK
49. Scuffman P.A., and Chaplin S. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK. PharmacoEconomics 22 8 (2004) 525-535
50. Stewart A., Sandercock J., Bryan S., Hyde C., Barton P.M., Fry-Smith A., et al. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review. Health Technol Assess 5 2 (2001)
51. Synnott H., Pollard D., Colgan P., and Fenton D. A survey of the impact of amending building regulations on radon concentrations in Irish homes. Proc 11th Congress of the International Radiation Association (IRPA11) Madrid (2004)
52. Trippoli S., Vaiani M., Lucioni C., and Messori A. Quality of life and utility in patients with non-small cell lung cancer. PharmacoEconomics 19 8 (2001) 855-863
53. Williams A. What could be nicer than NICE?. Office of Health Economics annual lecture (2004)
54. Wrixon A.D., Green B.M.R., Lomas P.R., Miles J.C.H., Cliff K.D., Francis E.A., et al. Natural radiation exposure in UK dwellings. National Radiological Protection Board (NRPB) report R190 (1988), NRPB, Chilton, Oxon, UK